Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole.
Published
Journal Article
Thirty patients with documented sporotrichosis were treated with 200-800 mg of fluconazole daily. Fourteen patients had lymphocutaneous infection; only five (36%) of these patients had any underlying illnesses. Sixteen patients had osteoarticular or visceral sporotrichosis; 12 (75%) of these patients had underlying diseases, mostly alcoholism, diabetes mellitus, and chronic obstructive pulmonary disease. Eleven of the 30 patients had relapsed after prior antifungal therapy. Most patients were treated with 400 mg of fluconazole; however, four received 200 mg of fluconazole daily for the entire course, and four received 800 mg of fluconazole daily for a portion of their therapy or for the entire course of therapy. Fluconazole therapy cured 10 (71%) of 14 patients with lymphocutaneous sporotrichosis. However, only five (31%) of 16 patients with osteoarticular or visceral sporotrichosis responded to therapy; the conditions of two of these five patients improved only, and there was no documented cure of their infections. With the exception of alopecia in five patients, toxic effects were minimal. Fluconazole is only modestly effective for treatment of sporotrichosis and should be considered second-line therapy for the occasional patient who is unable to take itraconazole.
Full Text
Duke Authors
Cited Authors
- Kauffman, CA; Pappas, PG; McKinsey, DS; Greenfield, RA; Perfect, JR; Cloud, GA; Thomas, CJ; Dismukes, WE
Published Date
- January 1, 1996
Published In
- Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
Volume / Issue
- 22 / 1
Start / End Page
- 46 - 50
PubMed ID
- 8824965
Pubmed Central ID
- 8824965
International Standard Serial Number (ISSN)
- 1058-4838
Digital Object Identifier (DOI)
- 10.1093/clinids/22.1.46
Language
- eng
Conference Location
- United States